---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000056"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T21:29:55.992706+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q2 beats with INGREZZA $440M (+26% YoY); raises 2023 sales forecast to $1.77-1.82B

## Summary
- Q2 total revenue $452.7M vs $378.2M YoY; GAAP EPS $0.95 vs loss of $0.18, non-GAAP EPS $1.25 vs $0.84.
- INGREZZA net product sales $440M (26% YoY); record new patient starts in Q2.
- 2023 INGREZZA guidance raised to $1.77-1.82B from prior range; reaffirms R&D and SG&A expense guidance.
- Cash, cash equivalents and marketable securities $1.32B at June 30, 2023; up from $1.29B at year-end 2022.
- PDUFA date for valbenazine in Huntington's chorea set for Aug 20, 2023; four Phase 2/3 readouts expected in Q4.

## SEC filing metadata
- accession: 0000914475-23-000056
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000056/0000914475-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000056/nbix-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000056
- JSON: https://secwatch.observer/filing/0000914475-23-000056.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.